The global malaria rapid diagnostic device market is set for further expansion, with several testing methods proving to be reliable and effective. In 2013, the number of tests performed with rapid diagnostic tools for malaria was up from 48 million to 319 million. The technology has many promises, including accessibility, reliability, and ease of use. It is a promising new commercial opportunity, especially as it can reach every malaria-affected individual on the planet. But how does it work?
The Gazelle is a battery-operated, magneto-optical point-of-care diagnostic device. The test provides results within one minute, compared to 30 minutes or more with microscopy and RDTs. In contrast, the PCR test requires a period of seven to eight hours. In addition, the Gazelle's performance and result rates were higher among patients without previous malaria infection. Despite these limitations, the device has demonstrated its clinical utility and is a welcome addition to the global malaria treatment pipeline.
This device has the potential to be an important alternative diagnostic tool in areas affected by Pfhrp-2 deletion, during mass surveys, or in low resource settings. As the parasite burden increases during the asexual amplification cycle, a rapid test may be the only way to salvage a negative diagnosis of malaria in some patients. The Gazelle was the first haemozoin-based diagnostic device to undergo field evaluation. It was also compared with RDTs and PCR for a comparison.
The major players in the malaria rapid diagnostic device market include Abbott Laboratories, Atomo Diagnostics, Bio-Rad Laboratories Inc., Drucker Diagnostics, and ERADA Technology Alliance. Other major players in the market include Omega Diagnostics Group Plc. and QIAGEN N.V. Further, the report analyzed the competitive dynamics in the global malaria rapid diagnostic device market. It is a comprehensive assessment of the disease-related industry.
The market for malaria rapid diagnostic devices is largely driven by the eradication of malaria. The WHO has reported that over 3 billion dollars are currently being invested in the eradication of malaria. This growth has been attributed to the increasing popularity of rapid diagnostic tests for malaria. Besides, the device also has the potential to significantly reduce the cost of healthcare in developing countries. The market for rapid diagnostic devices is expected to grow in the future.
The malaria rapid diagnostic device market is dominated by major players like Abbott Laboratories, Bio-Rad Laboratories Inc., and Drucker Diagnostics. Other major players in the market include ERADA Technology Alliance, a nonprofit organization that works to advance the field of diagnostics. Some of the key players in the market are:* A.D.C., X.C., Molecular Instruments, QIAGEN N.V.
The Malaria Rapid Diagnostic Devices Market report evaluates key variables driving the growth of the industry and identifies key challenges, opportunities, and regional markets. The study highlights the global market for this device, which is expected to grow at a CAGR of over 5% during the forecast period. The market is highly fragmented, but major players in the industry are strengthening their product portfolios and expanding their geographic presence to increase their share.
Leading companies in the malaria rapid diagnostic devices market include Abbott Laboratories, Atomo Diagnostics, Bio-Rad Laboratories Inc., Drucker Diagnostics, and ERADA Technology Alliance. In addition to these players, companies such as Omega Diagnosis Group Plc., QIAGEN N.V., and SD Biosensor Inc. are driving the industry. These companies have invested heavily in malaria rapid diagnostics technology.
Moreover, the growth of the market for malaria rapid diagnostics devices is projected to increase over the next five years. The COVID-19 coronavirus outbreak has spread across almost every country in the world Health Organization has declared it a public health emergency. The impacts are already beginning to be felt, and the market for malaria rapid diagnostic devices will witness rapid growth. Other factors driving the market include the increasing need for accurate diagnostics, technological advancement, and increased investment.
The growth of the Malaria rapid diagnostic devices market is primarily driven by the government's support and the increasing incidence of malaria disease. The growing number of patients in low-income regions and the development of new diagnostic methods is one of the major factors driving the market for these diagnostics. Besides the rising prevalence of malaria in the developing world, the rapid diagnosis methods have also become more accessible and cost-effective. A good device that can quickly diagnose the disease can save lives.
The malaria rapid diagnostic devices market is largely driven by the increasing incidence of malaria. The prevalence of malaria has been increasing across the world for the past decade, and the need for rapid diagnostics has helped prevent the disease. The growth of the malaria rapid diagnostic devices market is anticipated to continue at a healthy pace over the next five years. Several leading players are in the market for these diagnostic devices, and have a large share of the overall market.
The region with the highest CAGR over the forecast period is Asia-Pacific. The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The fast growth is attributed to the increasing awareness of malaria diagnostics. They allow patients to get the right treatment at the right time, and thus are a major part of the market in developing countries. There is also a steady growth in the Middle East and North America.